![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 9, 7209-7213, March 1, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
andFrom the Department of Biochemistry and Molecular Biology, Oklahoma Center for Medical Glycobiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104
Received for publication, December 19, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Pasteurella multocida Type D, a
causative agent of atrophic rhinitis in swine and pasteurellosis in
other domestic animals, produces an extracellular polysaccharide
capsule that is a putative virulence factor. It was reported previously
that the capsule was removed by treating microbes with heparin lyase
III. We molecularly cloned a 617-residue enzyme, pmHS, which is a
heparosan (nonsulfated, unepimerized heparin) synthase. Recombinant
Escherichia coli-derived pmHS catalyzes the polymerization
of the monosaccharides from UDP-GlcNAc and UDP-GlcUA. Other
structurally related sugar nucleotides did not substitute. Synthase
activity was stimulated about 7-25-fold by the addition of an
exogenous polymer acceptor. Molecules composed of ~500-3,000 sugar
residues were produced in vitro. The polysaccharide was
sensitive to the action of heparin lyase III but resistant to
hyaluronan lyase. The sequence of the pmHS enzyme is not very similar
to the vertebrate heparin/heparan sulfate glycosyltransferases, EXT1 and 2, or to other Pasteurella
glycosaminoglycan synthases that produce hyaluronan or chondroitin. The
pmHS enzyme is the first microbial dual-action glycosyltransferase to
be described that forms a polysaccharide composed of
Glycosaminoglycans
(GAGs)1 are long linear
polysaccharides consisting of disaccharide repeats that contain an
amino sugar (1, 2). Heparin/heparan
( The invasiveness and pathogenicity of certain Escherichia
coli strains has been attributed to their polysaccharide capsule (4). Two E. coli capsular types, K5 and K4, make polymers
composed of GAG-like polymers. The K5 capsular material is a
polysaccharide called heparosan, N-acetylheparosan, or
desulfoheparin, which is identical to mammalian heparin/heparan sulfate
except that the bacterial polymer is nonsulfated, and there is no
epimerization of GlcUA to iduronic acid (5). The E. coli K4
polymer is a nonsulfated chondroitin backbone decorated with fructose
side branches on the C3 position of the GlcUA residues (6).
The E. coli K5 capsule biosynthesis locus contains the open
reading frames KfiA-D (also called
Kfa in some reports; GenBankTM accession number
X77617). At first, KfiC was stated to be a dual-action
glycosyltransferase responsible for the alternating addition of both
GlcUA and GlcNAc to the heparosan chain (7). However, a later report by
the same group reported that another protein, KfiA, was actually the
Many Pasteurella multocida isolates produce GAG or GAG-like
molecules as assessed by enzymatic degradation and removal of the
capsule of living bacterial cells (9, 10). Carter Type A P. multocida, the major causative agent of fowl cholera and pasteurellosis, makes an HA capsule (11). A single polypeptide, the HA
synthase pmHAS, polymerizes the HA chain by transferring both GlcUA and
GlcNAc (12). Type F P. multocida, the minor fowl cholera
pathogen, produces a capsule composed of a nonsulfated chondroitin
sensitive to Flavobacterium chondroitin AC lyase (9, 13,
14). Again, a dual-action chondroitin synthase, pmCS, polymerizes the
chondroitin chain (14). The capsule of another distinct P. multocida, Type D, was reported to be sensitive to heparin lyase
III (9). In this report, we describe the identification and
characterization of pmHS, a dual-action heparosan synthase.
Materials and Pasteurella Strains--
Unless otherwise noted,
all chemicals were from Sigma or Fisher, and all molecular biology
reagents were from Promega. The wild-type encapsulated Type D P. multocida isolates P-934 (swine), P-3881 (bovine), P-4058
(rabbit), and P-5695 (swine) were obtained from the United States
Department of Agriculture collection (Ames, IA). The strains were grown
in brain heart infusion (Difco) at 37 °C.
Analysis of Genomic DNA and Isolation of Capsule
Biosynthesis Locus DNA--
Preliminary data from a Southern blot
analysis using pmHAS-based hybridization probes (12) suggested that the
Type A synthase and the putative Type D synthase were not very similar
at the DNA level. However, a PCR suggested that the UDP-glucose
dehydrogenase genes, which encode an enzyme that produces the
UDP-GlcUA precursor required for both HA and heparin biosynthesis, were
very homologous. In most encapsulated bacteria, the precursor-forming
enzymes and the transferases are located in the same operon. To make a
hybridization probe predicted to detect the capsule locus, Type D
chromosomal DNA served as a template in PCR reactions utilizing
degenerate oligonucleotide primers (sense:
GARTTYBTIMRIGARGGIAARGCIYTITAYGAY; antisense:
RCARTAICCICCRTAICCRAAISWXGGRTTRTTRTARTG, where I is Ino; R is Ado or
Guo; S is Cyd or Guo; W is Ado or Thd; and Y is Cyd or Thd)
corresponding to a conserved central region in many known UDP-glucose
dehydrogenase genes. The ~0.3-kb amplicon was generated using
Taq DNA polymerase (Fisher), gel-purified, and labeled with
digoxigenin (High Prime system, Roche Molecular Biochemicals).
A lambda library of Sau3A partially digested P-3881 DNA
(~4-9-kb average length insert) was made using the
BamHI-cleaved Expression of Recombinant P. multocida Heparosan
Synthase--
The pmHS ORF (617 amino acids) was amplified from the
various Type D genomic DNA templates by 18 cycles of PCR (16) with Taq polymerase. For constructing the full-length enzyme, the
sense primer (ATGAGCTTATTTAAACGTGCTACTGAGC) corresponded to the
sequence at the deduced amino terminus of the ORF and the antisense
primer (TTTACTCGTTATAAAAAGATAAACACGGAATAAG) encoded the carboxyl
terminus including the stop codon. In addition, a truncated version of pmHS was produced by PCR with the same sense primer but a different antisense primer (TATATTTACAGCAGTATCATTTTCTAAAGG) to yield a predicted 501-residue protein, DcbF (GenBankTM accession number
AAK17905; Ref. 15); this variant corresponds to residues 1-497 of pmHS
followed by the residues TFRK.
The amplicons were cloned using the pETBlue-1 acceptor system (Novagen)
according to the manufacturer's instructions. The Taq-generated single A overhang is used to facilitate the
cloning of the open reading frame downstream of the T7 promoter and the ribosome binding site of the vector. The ligated products were transformed into E. coli NovaBlue and plated on LB
carbenicillin (50 µg/ml) and tetracycline (13 µg/ml) under
conditions for blue/white screening. White colonies were analyzed by
PCR-based screening and restriction digestion. Plasmids with the
desired ORF were transformed into E. coli Tuner, the T7 RNA
polymerase-containing expression host, and maintained on LB
medium with carbenicillin and chloramphenicol (34 µg/ml) at
30 °C. Mid-log phase cultures were induced with
Assays for Heparosan Synthase Activity--
The incorporation of
radiolabeled monosaccharides from UDP-[14C]GlcUA and/or
UDP-[3H]GlcNAc precursors (PerkinElmer Life
Sciences) was used to monitor heparosan synthase activity.
Samples were usually assayed in a buffer containing 50 mM
Tris, pH 7.2, 10 mM MgCl2, 10 mM
MnCl2, 0-0.6 mM UDP-GlcUA, and 0-0.6
mM UDP-GlcNAc at 30 °C. Depending on the experiment, a
Type D acceptor polymer processed by extended ultrasonication of a
capsular polysaccharide preparation (isolated by cetylpyridinium
chloride precipitation of the spent Type D culture media, Ref. 14) was
also added to the reaction mixture. The reaction products were
separated from substrates by descending paper (Whatman 3M)
chromatography with ethanol, 1 M ammonium acetate, pH 5.5, development solvent (65:35). The origin of the paper strip was cut out,
eluted with water, and the incorporation of radioactive sugars into
polymer was detected by liquid scintillation counting with BioSafe II
mixture (Research Products International). The metal preference
of pmHS was assessed by comparing the signal from a no metal control
reaction (0.5 mM EDTA) to reactions containing 10-20
mM manganese, magnesium, or cobalt chloride. To test the transfer specificity of pmHS, various UDP-sugars (UDP-GalNAc, UDP-GalUA, or UDP-Glc) were substituted for the authentic heparosan precursors. The data from the recombinant construct containing the
pmHS gene from the P-4058 strain are presented, but the
results are similar to constructs derived from the P-934 or P-5695 strains.
Size Analysis and Enzymatic Degradation of Labeled
Polymers--
Gel filtration chromatography was used to analyze the
size distribution of the labeled polymers. Separations were performed with a Polysep-GFC-P 4000 column (300 × 7.8 mm; Phenomenex)
eluted with 0.2 M sodium nitrate at 0.6 ml/min.
Radioactivity was monitored with an inline Radioflow LB508 detector (EG
& G Berthold; 500-µl flow cell) using a Unisafe I mixture (1.8 ml/min; Zinsser). The column was standardized with fluorescein-labeled
dextrans of various sizes.
To further characterize the radiolabeled polymers, depolymerization
tests with specific glycosidases was performed. The high molecular
weight product was purified by paper chromatography. The origin of the
strips was washed with 80% ethanol and air-dried and then extracted
with water. The water extract was lyophilized, resuspended in a small
volume of water, and split into three aliquots. Two aliquots were
treated with glycolytic enzymes for 2 days at 37 °C
(Flavobacterium heparin lyase III, 6.7 milliunits/µl, 50 mM sodium phosphate, pH 7.6, or Streptomyces HA
lyase, 333 milliunits/µl, 50 mM sodium acetate, pH 5.8).
The last aliquot was mock-treated without enzyme in acetate buffer. The
aliquots were quenched with SDS and subjected to paper chromatography,
and the radiolabel at the origin was measured by liquid scintillation counting.
Molecular Cloning of the Type D P. multocida Heparosan
Synthase--
A PCR product that contained a portion of the Type D
UDP-glucose dehydrogenase gene was used as a hybridization probe to
obtain the rest of the Type D P. multocida capsular locus
from a lambda library. We found a functional heparosan synthase, which
we named pmHS, in several distinct Type D strains from different host
organisms isolated around the world. In every case, an open reading
frame of 617 residues with very similar amino acid sequence (98-99% identical) was obtained.
In the latter stages of our project, another group deposited a sequence
from the capsular locus of a Type D organism in GenBankTM
(15). In their annotation, the carboxyl terminus of the pmHS homolog is
truncated and mutated to form a 501-residue protein that was called
DcbF (GenBankTM accession number AAK17905). No functional
role for the protein except glycosyltransferase was described, and no
activity experiments were performed. As we describe later, membranes or cell lysates prepared from E. coli with the recombinant
dcbF gene do not possess heparosan synthase activity.
Another deduced gene recently uncovered by the University of Minnesota
in their Type A P. multocida genome project (17) called
pglA (GenBankTM accession number AAK02498) and
encoding 651 amino acids is also similar to pmHS (73% identical in the
major overlapping region). However, the pglA gene is not
located in the putative capsule locus. This group made no annotation of
the function of pglA. We have preliminary evidence that this protein
also polymerizes GlcUA and GlcNAc residues to form heparosan (data not
shown). We found that a Type D strain also appears to contain a
homologous pglA gene as shown by PCR and activity analysis
(data not shown).
The next best heterologous matches for the pmHS enzyme in the data base
are KfiA and KfiC proteins from E. coli K5; these two
proteins work together to make the heparosan polymer (7, 8). There is a
good overall alignment of the enzyme sequences if smaller portions of
the pmHS ORF are aligned separately with KfiA and KfiC (Fig.
1). Some of the most notable sequence
similarities occur in the regions containing variants of the
DXD amino acid sequence motif.
Heterologous Expression of a Functional P. multocida Heparosan
Synthase--
Membrane extracts derived from E. coli Tuner
cells containing the plasmid encoding pmHS but not samples from cells
with the vector alone synthesized polymer in vitro when
supplied with both UDP-GlcUA and UDP-GlcNAc simultaneously (Table
I). The identity of the polymer as
heparosan was verified by its sensitivity to Flavobacterium
heparin lyase III (~97% destroyed after treatment) and its
resistance to the action of Streptomyces HA lyase. No substantial incorporation of radiolabeled [14C]GlcUA into
polymer was observed if UDP-GlcNAc was omitted or if UDP-GalNAc was
substituted for UDP-GlcNAc. Conversely, in experiments using
UDP-[3H]GlcNAc, substantial incorporation of radiolabel
into the polymer was only noted when UDP-GlcUA was also present.
UDP-GalUA or UDP-Glc did not substitute for UDPGlcUA. No
polymerization or transferase activity was detected if the divalent
metal ions were chelated with EDTA. Maximal activity was observed in
reactions that contained Mn2+, but Mg2+
also supported substantial incorporation (65-85% maximal).
Cobalt was a weaker cofactor (~30% maximal).
The addition of the heparosan polymer acceptor increased sugar
incorporation catalyzed by pmHS at least 7-25-fold in comparison to
parallel reactions without acceptor (Fig.
2), analogous to observations of pmHAS
(18) and pmCS (14). The acceptor stimulation of activity is probably
due to the lower efficiency or slower rate of initiation of a new
polymer chain in comparison to the elongation stage in
vitro. The exogenous acceptor sugar probably associates with the
recombinant enzyme's binding site for the nascent chain and then is
elongated rapidly.
Analysis by gel filtration chromatography indicated that recombinant
pmHS produced long polymer chains (~1-3 × 103
monosaccharides or ~200-600 kDa) in vitro without
acceptor (Fig. 3). If an acceptor polymer
was supplied to parallel reaction mixtures, then higher levels of
shorter chains (~0.1-2 × 103 monosaccharides or
~20-400 kDa added to acceptor) were more rapidly produced.
Radioactivity from both labeled GlcUA and GlcNAc sugars co-migrated as
a single peak in all chromatography profiles. Some chains also appear
to be initiated de novo in reactions with an acceptor as
evidenced by the small peak of higher molecular weight material near
the void volume. Apparently, once pmHS either starts a new chain or
binds an existing chain, rapid elongation is performed.
We found in parallel tests that membranes or lysates prepared from
recombinant cells containing the predicted dcbF gene (a truncated version of pmHS in the same expression vector;
Ref. 15) do not exhibit heparosan synthase activity. Even with large amounts of total protein repeated polymerization was not observed, and
no significant radiolabel incorporation above background levels was noted.
In this report, we have molecularly cloned the dual-action
glycosyltransferase responsible for polymerizing the heparosan backbone
component of the Type D capsular polysaccharide. As discussed earlier,
the first 497 residues of the pmHS protein are virtually identical to
the hypothetical DcbF sequence. We have sequenced the DNA from the
equivalent P-934 isolate obtained from the same United States
Department of Agriculture collection as reported in Ref. 15 as well as
several other Type D strains, but our results do not agree with the
dcbF open reading frame. Adler and co-workers (15) appear to
have made a sequencing error that resulted in a frameshift mutation; a
conceptual premature termination led to the creation of the erroneously
truncated dcbF annotation.
Recently, we have determined that the
Pasteurella hyaluronan synthase, pmHAS, contains two active
sites in a single polypeptide by generating mutants that transfer only
GlcUA or only GlcNAc (19). Interestingly, mixing the two different
mutant pmHAS proteins reconstituted the HA synthase activity. We
hypothesized that one domain, called A1, is responsible for GlcNAc
transfer and that the other domain, called A2, is responsible for GlcUA
transfer (19). The chondroitin synthase, pmCS, transfers a different hexosamine, GalNAc, and also appears to contain a similar two-domain structure (14). The amino acid sequence of the heparosan synthase pmHS,
however, is very different from other Pasteurella GAG
synthases, pmHAS and pmCS. The pmHAS and pmHS enzymes both perform the
task of polymerizing the identical monosaccharides; HA and heparin only
differ with respect to their linkages. The creation of different anomeric linkages probably requires very distinct active sites because
of the disparity between a retaining (to form Two distinct regions of pmHS are similar to the E. coli K5
KfiA or KfiC proteins, suggesting the limits of the sugar transfer domains (Fig. 1). On the basis of sequence similarity, if the Kfi
studies are correct, then GlcUA transfer and GlcNAc transfer occur at
the amino and carboxyl portions of pmHS, respectively. The pmHS protein
may be the result of the fusion of two ancestral single-action enzymes.
The efficiency and convenience of combining the two required enzyme
activities into a single polypeptide seem clear, but as a
counterexample, the E. coli KfiA and KfiC proteins remain
separate entities.
Interestingly, pglA, a gene with no reported function from a
Type A isolate (17), is similar to the pmHS gene of a Type D
strain. In parallel expression experiments, PglA from Type A or D
strains also appears to be a heparosan synthase (data not shown). We
have sequencing and enzymology projects in progress to verify the open
reading frames and the activities of PglA. It is quite puzzling that
the Type A strain would have a heparosan synthase as well as the known
HA synthase. The major Type A capsular polymer was shown to be HA, but
in retrospect a small amount of heparosan would be difficult or
impossible to detect in these characterization studies (11). A possible
scenario for the presence of a heparosan synthase in the Type A
bacteria is that the pglA gene is repressed or silent and
not expressed in this host under laboratory conditions. The
pglA gene could also be a cryptic remnant from an ancestral
organism (i.e. before Types A and D diverged) that has been
maintained, and the gene product is still functional. Another
interesting possibility is that in Type A organisms, either the
pmHAS or the pglA gene is utilized at different
times depending on conditions or the stage of infection; using
different capsular polymers could serve as a phase-shift mechanism. We
are generating antibodies to the PglA and pmHS proteins to examine
these hypotheses.
Bacteria-derived heparosan may be converted by epimerization and
sulfation into a polymer that resembles the mammalian heparin and
heparan sulfate because all the modifying enzymes have been identified
(3). P. multocida Type D (or an improved recombinant version) may be a more economical and useful source of heparosan than
E. coli K5 for several reasons. The former microbe has a higher intrinsic biosynthetic capacity for capsule production. The
Pasteurella capsule radius often exceeds the cell diameter when observed by light microscopy of India ink-prepared cells. On the
other hand, visualization of the meager E. coli K5 capsule often requires electron microscopy. From a safety standpoint, E. coli K5 is a human pathogen, whereas Type D Pasteurella
has only been reported to cause disease in animals. Furthermore, with respect to recombinant gene manipulation to create better production hosts, the benefits of handling only a single gene encoding pmHS, a
dual-action synthase, in comparison to utilizing KfiA and C (and
probably KfiB) are obvious.
The discovery of pmHS expands the known GAG biosynthesis repertoire of
P. multocida. Depending on the Carter capsular type, this
widespread species produces HA, heparosan, or chondroitin. The use of
the three major vertebrate GAGs as capsular polymers certainly
strengthens the case for molecular mimicry or camouflage as a useful
strategy for bacterial pathogens.
4GlcUA-
4GlcNAc disaccharide repeats. In contrast, heparosan
biosynthesis in E. coli K5 requires at least two separate
polypeptides, KfiA and KfiC, to catalyze the same polymerization reaction.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
4GlcUA-
4GlcNAc)n, chondroitin
(
4GlcUA-
3GalNAc)n, and hyaluronan
(
4GlcUA-
3GlcNAc)n are three prevalent GAGs. In the
former two polymers, usually n = 20-100, although in
the case of HA, typically n= 103-4. In
vertebrates, one or more modifications including O-sulfation of certain hydroxyls, deacetylation and subsequent
N-sulfation, or epimerization of glucuronic acid to iduronic
acid are found in most GAGs except HA (3). A few clever microbes also
produce GAG chains, however sulfation or epimerization has not been
described. The GAGs in pathogenic bacteria are found as extracellular
polysaccharide coatings, called capsules, which serve as virulence
factors (4). The capsule is thought to assist in the evasion of host
defenses such as phagocytosis and complement. As the microbial
polysaccharide is identical or very similar to the host GAG, the
antibody response is either very limited or non-existent.
GlcNAc-transferase required for heparosan polymerization (8).
Therefore, at least these two enzymes, KfiA and KfiC, the
GlcUA-transferases, work in concert to form the disaccharide repeat.
Another deduced protein in the operon, KfiB, has been reported to
stabilize the enzymatic complex during elongation in vivo
but perhaps not participate directly in catalysis (8). The identity and
the sequence of the E. coli K4 capsular
glycosyltransferase(s) has not yet been reported.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Zap ExpressTM vector system
(Stratagene). The plaque lifts were screened by hybridization (5× SSC,
50 °C; 16 h) with the digoxigenin-labeled probe using the
manufacturer's guidelines for colorimetric development. E. coli XLI-Blue MRF' was co-infected with the purified, individual positive lambda clones and ExAssist helper phage to yield phagemids. The resulting phagemids were transfected into E. coli XLOLR
cells to recover the plasmids. Sequence analysis of the plasmids using a variety of custom primers as well as the GPS-1 Genome Priming System
(New England Biolabs) revealed a novel open reading frame, which we
called pmHS (DNA sequence facilities at Oklahoma State University and
the University of Oklahoma Health Sciences Center). We amplified and
sequenced the ORF from several highly encapsulated isolates (see next
section); very similar sequences were obtained.
-isopropylthiogalactoside (0.2 mM final) for 5 h.
The cells were harvested by centrifugation and frozen, and the
membranes were prepared according to a cold lysozyme/sonication method
(16) except that 0.1 mM mercaptoethanol was included during
the sonication steps. Membrane pellets were suspended in 50 mM Tris, pH 7.2, 0.1 mM EDTA, and protease inhibitors.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (45K):
[in a new window]
Fig. 1.
Sequence similarity of pmHS with KfiA and
KfiC. Elements of the Pasteurella heparosan synthase,
HS1 (containing residues 91-240) and HS2
(containing residues 491-540), are very similar to portions of two
proteins from the E. coli K5 capsular locus
(A, residues 75-172 of KfiA;
C, residues 262-410 of KfiC) as shown by this
modified Multalin alignment (Ref. 21; numbering scheme corresponds to
the pmHS sequence). The HS1 and HS2 elements may be important for
hexosamine transferase or for glucuronic acid transferase activities,
respectively. con, consensus symbols; asterisks,
(Lys or Arg) and (Ser or Thr); %, any one of Phe, Tyr, or Trp; $, any
one of Leu or Met; !, any one of Ile or Val; #, any one of Glu, Asp,
Gln, or Asn.
Transferase specificity of recombinant pmHS for sugar nucleotides

View larger version (14K):
[in a new window]
Fig. 2.
pmHS activity dependence on acceptor and
enzyme concentration. Various amounts of crude membranes
containing the full-length enzyme, pmHS-(1-617), were incubated
in 50 µl of buffer containing 50 mM Tris, pH 7.2, 10 mM MgCl2, 10 mM MnCl2,
500 µM UDP-[14C]GlcUA (0.15 µCi), and 500 µM UDP-GlcNAc. Three parallel sets of reactions were
performed with either no acceptor (circles) or two
concentrations of heparosan polymer acceptor (uronic acid: 0.6 µg,
squares; 1.7 µg, triangles). After 40 min, the
reaction was terminated and analyzed by paper chromatography. The
background incorporation due to vector membranes alone (630 µg of
total protein; not plotted) with the high concentration of the acceptor
was 75 dpm [14C]GlcUA. The activity of pmHS is greatly
stimulated by exogenous acceptor.

View larger version (19K):
[in a new window]
Fig. 3.
Gel filtration analysis of radiolabeled
polymer synthesized in vitro. The crude membranes
containing pmHS (0.7 mg of total protein) were incubated with
UDP-[14C]GlcUA and UDP-[3H]GlcNAc (500 µM, 0.4 µCi each) in a 200-µl reaction volume either
in the presence (top panel) or absence (bottom
panel) of acceptor polymer (1 µg of uronic acid). After various
reaction times (denoted on curves: 20,
60, or 270 min), portions of the
samples (75%) were analyzed on the PolySep column (calibration elution
times in minutes: void volume, 9.8; 580 kDa dextran, 12.3; 145 kDa
dextran, 12.75, totally included volume, 16.7). The starting acceptor
polymer eluted at 12.8 min. Large polymers composed of both
radiolabeled sugars (C, 14C; H,
3H) in an equimolar ratio were synthesized by pmHS.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-linkages) and an
inverting (to form
-linkages) transfer mechanism. The putative
dual-action vertebrate heparin synthases, EXT1 and 2, also
appear to have two transferase domains, but the amino acid sequences
are not similar to pmHS (20).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Tasha Arnett, Wei Jing, Ling Gao, and Deborah Spaulding for technical assistance and Dr. Kim Brogden and the late Dr. Richard Rimler for providing the Type D P. multocida strains and helpful advice.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant GM56497 and National Science Foundation Grant MCB-9876193 (to P. L. D.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF425591 and AF439804.
To whom correspondence should be addressed: Dept. of Biochemistry
and Molecular Biology, University of Oklahoma Health Sciences Center,
940 Stanton L. Young Blvd., Oklahoma City, OK 73104. Tel.: 405-271-2227; Fax: 405-271-3092; E-mail:
paul-deangelis@ouhsc.edu.
Published, JBC Papers in Press, December 26, 2001, DOI 10.1074/jbc.M112130200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GAG, glycosaminoglycan; HA, hyaluronan, hyaluronate, or hyaluronic acid; pmCS, P. multocida chondroitin synthase; pmHS, P. multocida heparosan synthase; pmHAS, P. multocida HA synthase; ORF, open reading frame.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Roden, L. (1980) in The Biochemistry of Glycoproteins and Proteoglycans (Lennarz, W. J., ed) , pp. 267-371, Plenum Publishing Corp., New York |
| 2. | Lidholt, K. (1997) Biochem. Soc. Trans. 25, 866-870[Medline] [Order article via Infotrieve] |
| 3. | Esko, J. D., and Lindahl, U. (2001) J. Clin. Invest. 108, 169-173[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Roberts, I. S. (1996) Annu. Rev. Microbiol. 50, 285-315[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Vann, W. F., Schmidt, M. A., Jann, B., and Jann, K. (1981) Eur. J. Biochem. 116, 359-364[Medline] [Order article via Infotrieve] |
| 6. | Rodriguez, M. L., Jann, B., and Jann, K. (1988) Eur. J. Biochem. 177, 117-124[Medline] [Order article via Infotrieve] |
| 7. |
Griffiths, G.,
Cook, N. J.,
Gottfridson, E.,
Lind, T.,
Lidholt, K.,
and Roberts, I. S.
(1998)
J. Biol. Chem.
273,
11752-11757 |
| 8. |
Hodson, N.,
Griffiths, G.,
Cook, N.,
Pourhossein, M.,
Gottfridson, E.,
Lind, T.,
Lidholt, K.,
and Roberts, I. S.
(2000)
J. Biol. Chem.
275,
27311-27315 |
| 9. | Rimler, R. B. (1994) Vet. Rec. 134, 191-192[Medline] [Order article via Infotrieve] |
| 10. | Rimler, R. B., Register, K. B., Magyar, T., and Ackermann, M. R. (1995) Vet. Microbiol. 47, 287-294[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Rosner, H., Grimmecke, H. D., Knirel, Y. A., and Shashkov, A. S. (1992) Carbohydr. Res. 223, 329-333[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
DeAngelis, P. L.,
Jing, W.,
Drake, R. R.,
and Achyuthan, A. M.
(1998)
J. Biol. Chem.
273,
8454-8458 |
| 13. |
Rimler, R. B.,
and Rhoades, K. R.
(1987)
J. Clin. Microbiol.
25,
615-618 |
| 14. |
DeAngelis, P. L.,
and Padgett-McCue, A. J.
(2000)
J. Biol. Chem.
275,
24124-24129 |
| 15. |
Townsend, K. M.,
Boyce, J. D.,
Chung, J. Y.,
Frost, A. J.,
and Adler, B.
(2001)
J. Clin. Microbiol.
39,
924-929 |
| 16. | DeAngelis, P. L., and Weigel, P. H. (1994) Biochemistry 33, 9033-9039[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
May, B. J.,
Zhang, Q., Li, L. L.,
Paustian, M. L.,
Whittam, T. S.,
and Kapur, V.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
3460-3465 |
| 18. |
DeAngelis, P. L.
(1999)
J. Biol. Chem.
274,
26557-26562 |
| 19. |
Jing, W.,
and DeAngelis, P. L.
(2000)
Glycobiology
10,
883-889 |
| 20. | Duncan, G., McCormick, C., and Tufaro, F. (2001) J. Clin. Invest. 108, 511-516[CrossRef][Medline] [Order article via Infotrieve] |
| 21. |
Corpet, F.
(1988)
Nucleic Acids Res.
16,
10881-10890 |
This article has been cited by other articles:
![]() |
A. E. Sismey-Ragatz, D. E. Green, N. J. Otto, M. Rejzek, R. A. Field, and P. L. DeAngelis Chemoenzymatic Synthesis with Distinct Pasteurella Heparosan Synthases: MONODISPERSE POLYMERS AND UNNATURAL STRUCTURES J. Biol. Chem., September 28, 2007; 282(39): 28321 - 28327. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Tracy, F. Y. Avci, R. J. Linhardt, and P. L. DeAngelis Acceptor Specificity of the Pasteurella Hyaluronan and Chondroitin Synthases and Production of Chimeric Glycosaminoglycans J. Biol. Chem., January 5, 2007; 282(1): 337 - 344. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Kane, C. L. White, and P. L. DeAngelis Functional Characterization of PmHS1, a Pasteurella multocida Heparosan Synthase J. Biol. Chem., November 3, 2006; 281(44): 33192 - 33197. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Williams, K. M. Halkes, J. P. Kamerling, and P. L. DeAngelis Critical Elements of Oligosaccharide Acceptor Substrates for the Pasteurella multocida Hyaluronan Synthase J. Biol. Chem., March 3, 2006; 281(9): 5391 - 5397. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. L. DeAngelis and C. L. White Identification of a Distinct, Cryptic Heparosan Synthase from Pasteurella multocida Types A, D, and F J. Bacteriol., December 15, 2004; 186(24): 8529 - 8532. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Saribas, A. Mobasseri, P. Pristatsky, X. Chen, R. Barthelson, D. Hakes, and J. Wang Production of N-sulfated polysaccharides using yeast-expressed N-deacetylase/N-sulfotransferase-1 (NDST-1) Glycobiology, December 1, 2004; 14(12): 1217 - 1228. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Jing and P. L. DeAngelis Analysis of the two active sites of the hyaluronan synthase and the chondroitin synthase of Pasteurella multocida Glycobiology, October 1, 2003; 13(10): 661 - 671. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |